Alvotech
Alvotech is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $1.33B market cap.
Most recent earnings call: Q1 FY26 on May 7, 2026.
16 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Spoken Alpha tracks ALVO's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 5/10 quarters with 30% positive reaction rate
SamplePeers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ALVO.
$ curl https://api.spokenalpha.com/v1/companies/ALVOFAQ
Spoken Alpha indexes ALVO's earnings call transcripts at https://spokenalpha.com/companies/ALVO. Each call links to attributed speakers and parsed analyst Q&A. Alvotech's own investor relations page is at https://investors.alvotech.com/.
Alvotech (ALVO) held its most recent earnings call on 2026-05-07, covering fiscal Q1 2026.
Alvotech (ALVO) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
Consistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Missed in 3 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.24 | $3.51 | -7.6% | -1.5% | +0.6% |
| Q4 FY2026 | $3.16 | $3.44 | -8.1% | 0.0% | -2.8% |
| Q3 FY2026 | $3.67 | $3.62 | +1.5% | +1.2% | +2.8% |
| Q2 FY2026 | $3.47 | $3.67 | -5.5% | -3.0% | -4.7% |
| Q1 FY2025 | $3.52 | $3.54 | -0.6% | -2.1% | -2.4% |
| Q4 FY2025 |
| $3.75 |
| $3.64 |
| +2.9% |
| -4.2% |
| -6.6% |
| Q3 FY2025 | $3.69 | $3.65 | +1.0% | +5.0% | +4.8% |
| Q2 FY2025 | $3.76 | $3.61 | +4.1% | +4.1% | +4.3% |
| Q1 FY2024 | $3.45 | $3.60 | -4.2% | -5.6% | -7.3% |
| Q4 FY2024 | $3.77 | $3.65 | +3.3% | -0.3% | +2.1% |